C
Cotherix
Affiliate of Actelion Pharmaceuticals Ltd, a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, that focuses on the discovery, development, and commercialization of innovative…
About Cotherix
CoTherix, a sister company of Actelion Pharmaceuticals US, Inc. and part of the Janssen Pharmaceutical Company of Johnson & Johnson, specializes in the distribution of authorized generic versions of pharmaceutical products. Located in South San Francisco, a hub for pharmaceutical and biotechnology development, CoTherix operates within the highly regulated pharmaceutical industry. The company ensures that its products meet stringent safety and regulatory standards, as evidenced by its involvement in the Bosentan REMS program, which includes all brand and generic bosentan products. This program is mandated by the FDA to manage the risks associated with hepatotoxicity and embryo-fetal toxicity. CoTherix's business model revolves around the distribution of these authorized generics, serving healthcare providers and patients who require these medications. The company generates revenue through the sale of these generic pharmaceuticals, leveraging its regulatory compliance and safety-focused approach to maintain market trust and reliability.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2000
- Headquarters
- San Francisco, United States
- Open positions
- None listed
- Dealroom signal
- 19.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Innovation Management, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2006 | $420M | — | Actelion Pharmaceuticals | — |
| IPOOther financing | Oct 2004 | $30M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Cotherix is 140 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
MPM BioImpact- TPThomas Weisel Venture Partners
Sofinnova Partners
Frazier Healthcare Partners
Other known investors2 additional known investors
Actelion Pharmaceuticals
Sofinnova Investments
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cotherix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cotherix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.